Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Haemonetics Earnings Call: Key Takeaways

Haemonetics delivered strong Q2 results with 10% organic revenue growth, raising full-year guidance driven by a major CSL relationship expansion and Persona Plus adoption despite near-term margin pressure from growth investments.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthPlasma 18%, Med Surge 6%, Blood Management 7%, Interventional Technologies 3%.
Mgmt ConfidenceHigh confidence in long-term high-20s operating margins despite near-term guidance cut.
Demand VisibilityStrong underlying plasma collections; CSL rollout confirmed through Q3 FY27.
Margin TrendsOperating margin guidance lowered to 0-50bps expansion from 50-100bps previously.
Op. LeverageExpect significant leverage in FY28 as transitory CSL ramp-up costs subside.
Pricing PowerPersona Plus improves customer economics by increasing plasma yield and productivity.
Vol vs PriceGrowth driven by share gains, Persona Plus adoption, and volume utilization.
Segment GrowthPlasma grew 18%; Transfusion Management grew double digits; Interventional Tech stabilized.
New ClientsExpanded CSL relationship; full Nexus PCS rollout to all US centers.
Capex & DebtRepaid $100M debt year-to-date; net leverage at 2.5x EBITDA.
RegulatoryReceived FDA approval for Vascade Elite; CE Mark for Vascade MVP XL.
CommentaryFocusing on turning durable revenue growth into lasting shareholder value.
New LaunchesLaunched Pace Pro Guide Wire and Vascade Elite for large bore.

Growth

Organic revenue grew 10% in Q2; Plasma segment led with 18% growth.

Outlook

Raised FY27 organic revenue guidance to 6-9% and EPS growth to 8-11%.

Risks

Management lowered operating margin guidance due to transitory CSL ramp-up costs and inflationary pressures.

Source

The company's earnings call, NYSE: HAE, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Haemonetics Corp: key numbers

Share price
$121.34Close, Nov 16
Market cap
$5.53B
Shares outstanding
45.54MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Haemonetics Corp

All →
4:17 PM ET Form 4
Insider Selling

Haemonetics VP, CAO Farris Maryanne Maunsell Sells $101K of Stock

Farris Maryanne Maunsell, VP, CAO, sold 836 shares of Haemonetics Corp at $120.99 a share, worth $101K in total on Nov 11, 2026. Shares held after the trade: 5,828 (-12.5%).

Value
$101K
Shares
836
Price
$120.99
Role
VP, CAO
Holding change
-12.5%
Trade date
Nov 11, 2026
6:07 AM ET 10-Q
Financial Results ▶ Call

Haemonetics Q2 2026 Results: Net Income $46.3M, Up 19.7% YoY

Haemonetics Corp reported net revenues of $357.8 million for the quarter ended September 26, 2026, a 9.3% increase compared to the prior year. Net income rose to $46.3 million, driven by higher gross profits and the absence of intangible asset impairments that occurred in the previous year's quarter.

Key figure
Net income $46.3M · +19.7% YoY
6:06 AM ET 8-K
Financial Results

Haemonetics Financial Results

Haemonetics reported second quarter fiscal 2027 revenue of $358 million, a 9% increase driven by strong performance in its Apheresis business. The company achieved GAAP diluted EPS of $1.00 and adjusted diluted EPS of $1.35, benefiting from gross margin expansion and the transformation of its product portfolio toward higher-margin offerings.

Term
Q2 2027

“Our second-quarter and first-half results reflect significant momentum across our businesses. Expansion of our CSL relationship and recent innovation milestones in both Apheresis and MedSurg strengthen our competitive position and create powerful new opportunities. With multiple catalysts for growth, we are focused on executing for our customers and translating our momentum into sustained success and shareholder value.”

Chris Simon, Haemonetics’ CEO
6:15 AM ET 8-K
Business Update

Haemonetics Business Update

Haemonetics provided a status update on its non-exclusive supply agreement with CSL Plasma, noting that CSL expects to complete the rollout of NexSys PCS devices and Persona PLUS disposables across all its U.S. collection centers by the end of 2027. The company maintained its existing fiscal 2027 guidance and plans to provide a detailed financial impact update during its November 2026 earnings call.

Counterparty
CSL Plasma Inc.
Term
through end of calendar year 2027

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.